Verbatim response from ChatGPT
Short answer
- Many people lose noticeable weight within the first 1–3 months on a GLP‑1 or GLP‑1/GIP (tirzepatide) drug. Typical trial averages are roughly 10–20% of starting body weight after ~1 year, depending on the drug and dose.
- That weight loss is generally maintained only while the drug is continued; stopping usually leads to partial or full regain unless lasting lifestyle changes or another strategy are in place.
What to expect (typical ranges from clinical trials)
- Semaglutide (Wegovy® is the 2.4 mg weight‑management formulation; Ozempic® is semaglutide for diabetes and often used off‑label): STEP trials showed average weight losses in the teens of percent of baseline weight over ~68 weeks (many participants lost ~10–15% at one year). Most loss happens in the first 4–6 months and then slows.
- Tirzepatide (Zepbound® for weight loss; Mounjaro® is the diabetes formulation used off‑label): SURMOUNT trials showed larger average losses — up to about 20% or more at the highest doses after ~72 weeks in some studies.
- Timing: people typically see a larger drop the first 3–6 months, then a slower continued decline through the first year. Individual results vary widely (dose, starting weight, diet/exercise, adherence, genetics, and side effects all change outcomes).
Sustainability — what the evidence shows
- Ongoing therapy: Trials show the best way to keep most of the weight off is to continue the medication plus lifestyle support.
- Stopping drug: Studies (for example STEP 4 with semaglutide) document weight regain after stopping the medication — often a substantial portion of the lost weight returns within months.
- Long‑term strategy: GLP‑1s are a highly effective tool, but for many people they function like a chronic therapy (similar to blood‑pressure or diabetes medicines). Combining medication with durable behavior change, structured nutrition, physical activity, and often ongoing medical follow‑up improves long‑term outcomes.
Safety, side effects, and practical points
- Common side effects: nausea, vomiting, diarrhea, constipation, and abdominal pain; these often lessen over weeks but can affect ability to tolerate therapy.
- Less common but important risks: gallbladder disease, pancreatitis, and in animal studies a thyroid C‑cell tumor signal (people with personal/family history of medullary thyroid carcinoma or MEN2 are typically advised not to use). Discuss risks with your clinician.
- Costs and access: branded products (Wegovy, Zepbound) can be expensive; insurance coverage varies. Some people use diabetes formulations off‑label (Ozempic, Mounjaro), which raises different access and safety considerations.
- Monitoring: baseline labs and periodic follow‑up (weight, glucose, kidney and liver function if indicated, and assessment of side effects) are recommended.
Practical next steps
- Talk with your prescribing clinician about realistic targets (e.g., 10–15% in the first year is common for semaglutide; higher for tirzepatide), how treatment will be stopped or continued, and a plan for maintenance.
- If you want, tell me your starting weight and which drug/dose you’re considering and I can give a personalized example of what a 10% or 20% loss would look like and a rough month-by-month estimate.